Professor Anthony Chalmers
Clinical and Brain Cancer Scientific Advisor
Anthony is a clinician scientist specializing in preclinical and clinical testing of novel drug-radiotherapy combinations aimed at improving outcomes for patients with glioblastoma (GBM). He is an acknowledged international leader in the field of radiotherapy/chemotherapy/PARP inhibitor combinations and novel DNA damage response treatments for GBM, and is the Director of the Cancer Research UK RadNet Centre Glasgow.
He is Chief Investigator of the PARADIGM and PARADIGM -2 studies of the PARP inhibitor olaparib in GBM, and co-chief investigator of a phase I first-in-human study evaluating the novel ATM inhibitor AZD1390 in combination with radiotherapy in GBM and brain metastases. He also led the OPARATIC study that evaluated olaparib with temozolomide in recurrent GBM. In addition to his clinical trial portfolio he has published widely on pre-clinical and mechanistic aspects of the DNA damage response in GBM.
